Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7823)
All Articles published online
|
Publishing Process of This Article
|
Sep 27, 2013 (publication date) through Dec 7, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World J Hepatol 2013; 5(9): 496-504 [PMID: 24073301 DOI: 10.4254/wjh.v5.i9.496] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v5/i9/496.htm |
| Number | Citing Articles |
| 1 |
Seung Kak Shin, Soo Yong Park, Young Kul Jung, Eui Joo Kim, Heon Nam Lee, Jong Joon Lee, Oh Sang Kwon, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim. Prevalence, Risk Factors and Clinical Characteristics in Patients with Genotype 6 Chronic Hepatitis C: A Single Institute Experience. The Korean Journal of Gastroenterology 2015; 65(2): 105 doi: 10.4166/kjg.2015.65.2.105
|
| 2 |
Mei-Hsuan Lee, Tiffany I Hsiao, Shreenidhi R Subramaniam, An K Le, Vinh D Vu, Huy N Trinh, Jian Zhang, Mingjuan Jin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Mindie H Nguyen. HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. American Journal of Gastroenterology 2017; 112(7): 1111 doi: 10.1038/ajg.2017.123
|
| 3 |
Phuong Nguyen Thi Thu, Mai Ngo Thi Quynh, Linh Pham Van, Hung Nguyen Van, Hoi Nguyen Thanh, Fu-Ming Tsai. Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study. BioMed Research International 2022; 2022: 1 doi: 10.1155/2022/6054677
|
| 4 |
Kok-Siong Poon, Julian Wei-Tze Tang, Evelyn Siew- Chuan Koay. Bioinformatics Tools for Detection and Clinical Interpretation of Genomic Variations. 2019; doi: 10.5772/intechopen.84577
|
| 5 |
V. Saxena, M. M. Manos, H. S. Yee, L. Catalli, E. Wayne, R. C. Murphy, V. A. Shvachko, M. P. Pauly, J. Chua, A. Monto, N. A. Terrault. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Alimentary Pharmacology & Therapeutics 2014; 39(10): 1213 doi: 10.1111/apt.12718
|
| 6 |
Xiwei Wang, Fen Liu, Fang Wei, Hong Ren, Huaidong Hu, Wenzhe Ho. Efficacy and Safety of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 6: A Meta-Analysis. PLoS ONE 2014; 9(6): e100128 doi: 10.1371/journal.pone.0100128
|
| 7 |
Aung H. Bwa, Gayatri Nangia, Si T.S. Win, Soe T. Maung, Khin A.W. Han, Su S. Htar, Lei Y. Wine, Wint W. Ko, Moe P. Oo, Naomi K.T. Hlaing, Julia Palecki, Bao L. Loza, Khin M. Win, Rajender Reddy. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience. Journal of Clinical and Experimental Hepatology 2019; 9(3): 283 doi: 10.1016/j.jceh.2018.12.001
|
| 8 |
|
| 9 |
Nattiya Kapol, Surasit Lochid-amnuay, Yot Teerawattananon. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. BMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0506-4
|
| 10 |
Filippo Ansaldi, Andrea Orsi, Laura Sticchi, Bianca Bruzzone, Giancarlo Icardi. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World Journal of Gastroenterology 2014; 20(29): 9633-9652 doi: 10.3748/wjg.v20.i29.9633
|
| 11 |
Joseph Mwangi, Zipporah Nganga, Solomon Mpoke, Raphael Lihana, Joyceline Kinyua, Nancy Lagat, Joseph Muriuki, Rency Lel, Sheila Kageha, Saida Osman, Hiroshi Ichimura. Hepatitis C virus genotypes in Kenya. Archives of Virology 2016; 161(1): 95 doi: 10.1007/s00705-015-2623-8
|
| 12 |
Vasilios Papastergiou, Stylianos Karatapanis. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World Journal of Clinical Cases 2015; 3(3): 210-220 doi: 10.12998/wjcc.v3.i3.210
|
| 13 |
Chun‐Han Cheng, Huan‐Lin Chen, I‐Tsung Lin, Chia‐Hsien Wu, Yuan‐Kai Lee, Ming‐Wun Wong, Ming‐Jong Bair. The genotype distribution of hepatitis C in southeastern Taiwan: Clinical characteristics, racial difference, and therapeutic response. The Kaohsiung Journal of Medical Sciences 2015; 31(11): 597 doi: 10.1016/j.kjms.2015.09.006
|
| 14 |
Chalermrat Bunchorntavakul, K. Rajender Reddy. Liver Disorders. 2017; : 143 doi: 10.1007/978-3-319-30103-7_11
|
| 15 |
Chengguang Hu, Guosheng Yuan, Junwei Liu, Huaping Huang, Yanyu Ren, Yinping Li, Xuefu Chen, Wei Li, Tao Wu, Hong Deng, Yanzhong Peng, Yong-Yuan Zhang, Yuanping Zhou. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China. Canadian Journal of Gastroenterology and Hepatology 2018; 2018: 1 doi: 10.1155/2018/3908767
|
| 16 |
Winifred Nyinoh Iveren. Genotypic variation, demographic characteristics and risk factors of hepatitis C virus in Scotland. Journal of Public Health and Epidemiology 2018; 10(7): 241 doi: 10.5897/JPHE2018.1031
|
| 17 |
Jyh-Jou Chen, Yen-Cheng Chiu, Pei-Lun Lee, Hung-Da Tung, Hung-Chih Chiu, Shih-Chieh Chien, Pin-Nan Cheng. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. Journal of the Formosan Medical Association 2022; 121(11): 2265 doi: 10.1016/j.jfma.2022.04.020
|
| 18 |
Pham Thi Thu Thuy, Chalermrat Bunchorntavakul, Ho Tan Dat, Julia Palecki, K Rajender Reddy. Sofosbuvir-Ledipasvir with or without Ribavirin for Chronic Hepatitis C Genotype-1 and 6: Real-World Experience in Vietnam. Antiviral Therapy 2018; 23(5): 415 doi: 10.3851/IMP3217
|
| 19 |
Panita Mettikanont, Chalermrat Bunchorntavakul, K. Rajender Reddy. Systematic review: epidemiology and response to direct‐acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Alimentary Pharmacology & Therapeutics 2019; 49(5): 492 doi: 10.1111/apt.15100
|
| 20 |
Hsin-Yun Sun, Chien-Yu Cheng, Chi-Ying Lin, Chia-Jui Yang, Nan-Yao Lee, Bo-Huang Liou, Hung-Jen Tang, Yuang-Meng Liu, Chun-Yuan Lee, Tun-Chieh Chen, Yi-Chia Huang, Yuan-Ti Lee, Ming-Jui Tsai, Po-Liang Lu, Hung-Chin Tsai, Ning-Chi Wang, Tung-Che Hung, Shu-Hsing Cheng, Chien-Ching Hung. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. World Journal of Gastroenterology 2022; 28(11): 1172-1183 doi: 10.3748/wjg.v28.i11.1172
|
| 21 |
Cecilia M. Shikuma, Thuy Le, Thao Vu Phuong, Glen M. Chew, Van Vinh Chau Nguyen, Trieu Ly Vo, Chathura Siriwardhana, Dominic Chow, Hayk Ghukasyan, Nath Limpruttidham, Thomas Premeaux, Louie Mar Gangcuangco, Robert Paul, Lishomwa C. Ndhlovu. Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. AIDS Research and Human Retroviruses 2022; 38(6): 441 doi: 10.1089/aid.2021.0076
|
| 22 |
Mohit Bhatia, Ekta Gupta. Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature. Journal of Family Medicine and Primary Care 2020; 9(2): 531 doi: 10.4103/jfmpc.jfmpc_943_19
|
| 23 |
Saba Farooq, Sirmast Faiz, Atia-tul Wahab, M. Iqbal Choudhary. Determination of hepatitis C virus subtype prevalent in Sindh, Pakistan: a phylogenetic analysis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-59342-7
|
| 24 |
Narayana Murthy Ganta, Gangaraju Gedda, Bethi Rathnakar, Mavurapu Satyanarayana, Bhaskar Yamajala, Mohamed Jawed Ahsan, Surender Singh Jadav, Tuniki Balaraju. A review on HCV inhibitors: Significance of non-structural polyproteins. European Journal of Medicinal Chemistry 2019; 164: 576 doi: 10.1016/j.ejmech.2018.12.045
|